Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487897 · ClinicalTrials.gov registry record · Phase 3
Phase III Presbyopia Correction Using the VIS Opti-K™ System
A Phase 3 study of Presbyopia, sponsored by VIS.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 4
- Study locations
NCT06487897 is a Phase 3 study of Presbyopia that is actively recruiting participants, run by VIS. The registered enrollment target is 75 participants, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06487897, a Phase 3 study of Presbyopia, is actively recruiting participants, sponsored by VIS.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main questions it aims to answer are determining uncorrected near visual acuity at 40cm in the treated eye and subjective improvement as measured by the patient satisfaction questionnaire.
Conditions Studied
Interventions
- DEVICE Optimal laser keratoplasty
Study Locations (4)
Florida
- Cohen Laser & Vision Center - Boca Raton
Massachusetts
- Claris Vision Eye Health - South Dartmouth
New Jersey
- The Cornea & Laser Eye Institute - Teaneck
New York
- OCLI Vision - Oceanside - Oceanside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06487897
The ClinicalTrials.gov registry entry for NCT06487897 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 269-participant average among 38 other Presbyopia trials with a reported enrollment target (72% lower). The listed sponsor is VIS, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Presbyopia appearing as the primary indexed condition, and to 1 intervention - of which Optimal laser keratoplasty is the first listed.
NCT06487897 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06487897 about?
NCT06487897 is a clinical study titled "Phase III Presbyopia Correction Using the VIS Opti-K™ System". The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main question...
What is the current status of trial NCT06487897?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2024-09-30. Estimated completion is 2027-12.
What conditions does trial NCT06487897 study?
This clinical trial studies the following conditions: Presbyopia.
What interventions are being tested in trial NCT06487897?
The interventions under investigation include: Optimal laser keratoplasty (DEVICE).
Who is sponsoring clinical trial NCT06487897?
This trial is sponsored by VIS, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487897 being conducted?
This trial has 4 study locations across Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Presbyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
COMPLETED · Phase 3
-
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
COMPLETED · Phase 3
-
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
COMPLETED · Phase 3
-
An Evaluation of the Efficacy and Safety of CSF-1 in the Temporary Correction of Presbyopia (NEAR-2)
COMPLETED · Phase 3
-
Post Market Clinical Evaluation of Clareon PanOptix Pro and Clareon PanOptix Pro Toric IOLs
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.